Metformin Class Action Canada
Rice Harbut Elliott LLP is investigating a possible class action lawsuit, representing Canadians who were prescribed metformin containing a nitrosamine impurity called N-nitrosodimethylamine (NDMA) above the acceptable limit. Drugs containing metformin are used to treat patients with diabetes. At present, the recall involves the following metformin products:
|Company||Product name/Active Pharmaceutical Ingredient (API)||DIN||Strength||Lot #||Expiry|
|Apotex Inc.||APO-Metformin ER (Metformin Hydrochloride Extended-Release Tablets)||02305062||500 mg||NV3242||04/2020|
|Ranbaxy Pharmaceuticals Canada Inc.||RAN-Metformin||02269031||500 mg||AJY8006A||05/2020|
The full details of the Health Canada recall can be found here.
Our firm is seeking compensation for persons who received any of the above-listed drugs. Damages will be sought for individuals who were diagnosed with cancer and other individuals who received the drugs that were recalled. The latter group may be entitled to compensation pursuant to B.C. consumer protection legislation.
If you received any of the above-listed drugs, you may be affected by this class action lawsuit. Please fill out the form below to get in touch with us. Joining our contact list creates no financial obligation and we will keep all the information that you provide to us confidential.
If you have any recalled Metformin please preserve it as we may wish to arrange testing to determine the levels of toxins in the medication.
Who qualifies for this Class Action?
Canadians who purchased and ingested Metformin on the recall list – https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/72287a-eng.php
Objectives of Class Action?
Compensation for personal injury or refunds for persons who purchased and/or ingested recalled Metformin